Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases
Forecasted Federal grant Posted
- Opportunity number
- PAR-27-109
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications expected due
- Award size
- $300,000 to $600,000
Opportunity facts
- Expected posting
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- For Profit Organizations
- City/Township Governments
- Small Businesses
- Tribal Governments (Federally Recognized)
- Public or Indian Housing Auth.
- Higher Education Inst. (Private)
- 501(c)(3) Nonprofits
- Other
- Tribal Organizations (Not Federally Recognized)
- Special District Governments
- State Governments
- Higher Education Inst. (Public)
- County Governments
- Non-501(c)(3) Nonprofits
- Independent School Districts
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity to solicit applications for Exploratory Clinical Trials Grants supporting clinical research in arthritis, musculoskeletal, and skin diseases; a hard deadline has not yet been announced.
Eligible applicants include for-profit organizations, small businesses, higher education institutions (public and private), city and county governments, state governments, tribal governments (federally recognized and not federally recognized), Indian tribal organizations, 501(c)(3) and non-501(c)(3) nonprofits, special district governments, public or Indian housing authorities, independent school districts, eligible federal agencies, U.S. territories or possessions, faith-based and community-based organizations, regional organizations, and non-domestic entities.
The program funds short-term, interventionist clinical trials meeting the NIH definition of a clinical trial and feasible within time and budget constraints. Priority areas include proof-of-concept and first-in-human studies; Phase I and Phase II trials; dose-finding, escalation, tolerability, safety, and efficacy studies with drugs, biologics, devices, behavioral interventions, and physical therapy; clinical trials generating data for subsequent robust trials; and trials in rare diseases with limited participant populations. The program emphasizes translating promising laboratory, preclinical, and early human testing findings into clinical practice.
The opportunity falls under CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research). Award amounts, period of performance, number of expected awards, and evaluation criteria are not yet specified in this forecast stage. The NIAMS has historically dispersed awards ranging from approximately $43,000 to over $2 million under this program.
Forecast synopsis
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for Exploratory Clinical Trials Grants Program in the mission areas of NIAMS. The goal of the NIAMS clinical trial program is to support research leading to the prevention or reduction of symptoms and improve outcomes and function in patients with rheumatic, musculoskeletal, or skin conditions or diseases. The purpose of the Exploratory Clinical Trials Grants Program is to foster clinical trials that will lead to clinically meaningful improvements in prevention, diagnosis, or treatment of these conditions or diseases.
This Exploratory Clinical Trials Grants Program is designed to facilitate the execution of short-term, interventional studies. The Program is intended to support a range of exploratory studies, from proof-of-concept/first in human to Phase I and Phase II clinical trials. Such studies must meet the NIH definition of a clinical trial and be feasible within the time and budget constraints of this NOFO. A high priority is the use of such studies to stimulate the translation of promising research developments from laboratory, preclinical, and early human testing into clinical practice.
Examples of research areas of interest include, but are not limited to:
- Conducting early-stage clinical trials, such as but not limited to; first in human, dose-finding or escalation/tolerability/safety/efficacy studies with drugs, biologics, devices, behavioral interventions, and/or physical therapy for treatment of arthritis, musculoskeletal, or skin conditions or diseases.
- Clinical trials to provide data required to support a future, more robust clinical trial whose aim is to help establish the safety and efficacy or effectiveness of an intervention.
- Clinical trials in rare diseases where the number of potential study participants is limited.
- Clinical trials to determine the predictive value of a potential biomarker.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity